CA2155005A1 - Pharmaceutical Compositions Containing Bactericidal Permeability Increasing Protein and a Surfactant - Google Patents
Pharmaceutical Compositions Containing Bactericidal Permeability Increasing Protein and a SurfactantInfo
- Publication number
- CA2155005A1 CA2155005A1 CA2155005A CA2155005A CA2155005A1 CA 2155005 A1 CA2155005 A1 CA 2155005A1 CA 2155005 A CA2155005 A CA 2155005A CA 2155005 A CA2155005 A CA 2155005A CA 2155005 A1 CA2155005 A1 CA 2155005A1
- Authority
- CA
- Canada
- Prior art keywords
- bpi
- permeability increasing
- pharmaceutical compositions
- surfactant
- compositions containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Bactericidal/permeability increasing (BPI) polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising the polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate suractants. Preferred BPI polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, and biologically active analogs of BPI.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1236093A | 1993-02-02 | 1993-02-02 | |
US08/012,360 | 1993-02-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2155005A1 true CA2155005A1 (en) | 1994-08-18 |
CA2155005C CA2155005C (en) | 1999-04-06 |
Family
ID=21754603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002155005A Expired - Fee Related CA2155005C (en) | 1993-02-02 | 1994-02-02 | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
Country Status (13)
Country | Link |
---|---|
US (5) | US5488034A (en) |
EP (1) | EP0682524B1 (en) |
JP (2) | JP3946246B2 (en) |
CN (1) | CN1163264C (en) |
AT (1) | ATE206308T1 (en) |
AU (1) | AU695125B2 (en) |
CA (1) | CA2155005C (en) |
DE (1) | DE69428521T2 (en) |
DK (1) | DK0682524T3 (en) |
ES (1) | ES2164098T3 (en) |
HK (1) | HK1014156A1 (en) |
PT (1) | PT682524E (en) |
WO (1) | WO1994017819A1 (en) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
US6153193A (en) * | 1993-04-28 | 2000-11-28 | Supratek Pharma Inc. | Compositions for targeting biological agents |
US6277410B1 (en) | 1992-10-08 | 2001-08-21 | Supratek Pharma Inc. | Copolymer compositions for oral delivery |
US5420019A (en) | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
EP0682524B1 (en) * | 1993-02-02 | 2001-10-04 | XOMA Technology Ltd. | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US6214789B1 (en) | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
AU7175694A (en) | 1993-06-17 | 1995-01-17 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
US5770561A (en) * | 1993-07-14 | 1998-06-23 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
WO1995002414A1 (en) * | 1993-07-14 | 1995-01-26 | Xoma Corporation | Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products |
US6759203B1 (en) | 1993-09-22 | 2004-07-06 | Xoma Corporation | Method for quantifying BPI in body fluids |
DE69430823T2 (en) * | 1993-09-22 | 2003-02-20 | Xoma Technology Ltd | METHOD FOR TREATING GRAM-NEGATIVE BACTERIA INFECTION BY ADMINISTERING BACTERIA-KILLING / PLEASUREABILITY (BPI) PROTEIN PRODUCT AND ANTIBIOTIC |
CN1133634A (en) * | 1993-09-22 | 1996-10-16 | 爱克斯欧玛公司 | Method for quantifying BPI in body fluids |
EP0754049B1 (en) * | 1994-01-14 | 2002-04-03 | XOMA Technology Ltd. | Anti-fungal methods and materials |
DK0754050T3 (en) * | 1994-01-14 | 2002-10-21 | Xoma Technology Ltd | Anti-gram-positive bacterial methods and materials |
US5447913A (en) | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US5830860A (en) * | 1994-03-24 | 1998-11-03 | Regents Of The University Of Minnesota | Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5932544A (en) * | 1994-05-31 | 1999-08-03 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
US6271203B1 (en) | 1994-07-07 | 2001-08-07 | Xoma Corporation | Anti-protozoan methods and materials |
US5646114A (en) * | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
US6221959B1 (en) | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
US6353055B1 (en) | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
US5912228A (en) * | 1995-01-13 | 1999-06-15 | Xoma Corporation | Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products |
US5494896A (en) * | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
JP2001520631A (en) * | 1995-07-20 | 2001-10-30 | ゾーマ コーポレイション | Antifungal peptide |
US5686414A (en) * | 1995-11-14 | 1997-11-11 | Xoma Corporation | Methods of treating conditions associated with corneal transplantation |
JP2000501386A (en) * | 1995-11-14 | 2000-02-08 | ゾーマ コーポレイション | Bactericidal / permeability enhancing (BPI) protein for treating conditions associated with corneal injury |
DE69703689T2 (en) * | 1996-05-10 | 2001-05-10 | Xoma Technology Ltd | THERAPEUTIC APPLICATIONS OF BPI PROTEIN PRODUCTS FOR TREATING HUMAN MENINGOCOCCÄMIA |
US5741779A (en) | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
AU736096B2 (en) * | 1996-05-23 | 2001-07-26 | Xoma Corporation | Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma |
JP2000511892A (en) | 1996-05-24 | 2000-09-12 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Synthesis of soluble beta-sheet forming peptide |
US5888973A (en) * | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
WO1998013069A2 (en) | 1996-09-09 | 1998-04-02 | Supratek Pharma, Inc. | Fluorinated copolymeric pharmaceutical adjuncts |
US6482796B2 (en) * | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
AU744918B2 (en) * | 1996-11-01 | 2002-03-07 | Xoma Corporation | Therapeutic uses of BPI protein products in cystic fibrosis patients |
US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
FR2764800B1 (en) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURAN DERIVATIVES |
US5990082A (en) | 1997-10-22 | 1999-11-23 | Xoma Corporation | Uses of lipopolysaccharide binding protein |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US20030166525A1 (en) * | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
EP1173195B1 (en) * | 1999-04-21 | 2007-10-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS |
US6413537B1 (en) | 2000-03-10 | 2002-07-02 | Wisconsin Alumni Research Foundation | Nystatin formulation having reduced toxicity |
US7256180B2 (en) | 2000-04-28 | 2007-08-14 | Supratek Pharma Inc. | Compositions and methods for inducing activation of dendritic cells |
CN1604788B (en) * | 2001-10-16 | 2013-04-17 | 里克斯金蒂克斯公司 | High-concentration protein formulations and method of manufacture |
WO2003070751A2 (en) | 2002-02-20 | 2003-08-28 | Regents Of The University Of Minnesota | Partial peptide mimetics and methods |
WO2004007520A2 (en) * | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
DK1567191T3 (en) * | 2002-11-26 | 2011-01-03 | Eurocine Vaccines Ab | New amine-based adjuvant |
EP1598074B1 (en) * | 2003-02-28 | 2019-01-02 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
MXPA05010635A (en) * | 2003-04-02 | 2005-12-12 | Ares Trading Sa | Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant. |
US7838721B2 (en) * | 2003-04-09 | 2010-11-23 | Paragon Trade Brands, Llc | Disposable articles using high column AUL superabsorbents |
EP1638595B1 (en) * | 2003-06-20 | 2013-03-20 | Ares Trading S.A. | Freeze-dried fsh / lh formulations |
US8377459B2 (en) * | 2003-07-09 | 2013-02-19 | The Procter & Gamble Company | Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin |
US20050220881A1 (en) * | 2003-10-10 | 2005-10-06 | Bvm Holding Co. | Pharmaceutical composition |
US7150995B2 (en) * | 2004-01-16 | 2006-12-19 | Metrika, Inc. | Methods and systems for point of care bodily fluid analysis |
EP1778279B1 (en) * | 2004-08-04 | 2014-12-03 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
PT2813239T (en) * | 2004-08-04 | 2017-06-09 | Ipsen Biopharm Ltd | Pharmaceutical composition containing botulinum neurotoxin a2 |
US20060173428A1 (en) * | 2005-02-02 | 2006-08-03 | Acors Deanna M | Absorbent article with logically correlated image and textual graphics |
US7964200B2 (en) | 2005-05-18 | 2011-06-21 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against Chlamydia infection |
CU23432B6 (en) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | STABILIZED FORMULATIONS CONTAINING GAMMA AND ALFA INTERFERONS IN POTENTIAL PROPORTIONS |
WO2009021173A1 (en) * | 2007-08-08 | 2009-02-12 | Advanced Liquid Logic, Inc. | Use of additives for enhancing droplet operations |
WO2009034958A1 (en) * | 2007-09-12 | 2009-03-19 | Jsr Corporation | Protein stabilizer, method for producing the same, method for using protein stabilizer, and method for stabilizing protein |
EP2310412B1 (en) | 2008-06-20 | 2018-02-21 | Novartis AG | Immunoglobulins with reduced aggregation |
KR20180056805A (en) | 2009-06-04 | 2018-05-29 | 노파르티스 아게 | METHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATION |
RS61683B1 (en) | 2010-06-25 | 2021-05-31 | Shire Human Genetic Therapies | Cns delivery of therapeutic agents |
BR112013006088B1 (en) | 2010-09-15 | 2022-06-14 | Randall J Mrsny | ISOLATED DELIVERY CONSTRUCTION AND PHARMACEUTICAL COMPOSITION |
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
GB201116271D0 (en) * | 2011-09-21 | 2011-11-02 | Univ Cardiff | Dispersion anaesthetic device |
IL285716B (en) | 2014-05-07 | 2022-09-01 | Applied Molecular Transp Llc | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
PT3762009T (en) | 2018-03-08 | 2022-08-22 | Applied Molecular Transport Inc | Toxin-derived delivery constructs for oral delivery |
EP4316586A2 (en) | 2018-03-08 | 2024-02-07 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
BR112022002962A2 (en) | 2019-08-16 | 2022-07-05 | Applied Molecular Transport Inc | COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKIN |
CN115666522A (en) * | 2020-03-18 | 2023-01-31 | Gi医诺微新 | Fusion protein formulations comprising IL-2 protein and CD80 protein |
BR112023019201A2 (en) * | 2021-03-24 | 2023-10-17 | Japan Chem Res | AQUEOUS PHARMACEUTICAL COMPOSITION OR FREEZE DRIED PHARMACEUTICAL COMPOSITION |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3839314A (en) * | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US4478829A (en) * | 1983-04-28 | 1984-10-23 | Armour Pharmaceutical Company | Pharmaceutical preparation containing purified fibronectin |
US4933179A (en) * | 1983-08-22 | 1990-06-12 | Syntex (U.S.A.) Inc. | Feline leukemia virus antigen vaccines |
DE3406497A1 (en) * | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | HIGHLY DISPERSAL PHARMACEUTICAL MULTI-COMPONENT SYSTEMS AND METHOD FOR THEIR PRODUCTION |
US5234683A (en) * | 1985-06-18 | 1993-08-10 | Emory University | Method of stimulating the immune system |
US5039520A (en) * | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
US5152979A (en) * | 1986-05-15 | 1992-10-06 | Emory University | Method for treating vascular obstructions caused by abnormal cells |
US5041288A (en) * | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
US5071649A (en) * | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
US5182106A (en) * | 1986-05-15 | 1993-01-26 | Emory University | Method for treating hypothermia |
FR2608988B1 (en) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES |
FR2634397B2 (en) * | 1986-12-31 | 1991-04-19 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF DISPERSIBLE COLLOIDAL SYSTEMS OF A PROTEIN IN THE FORM OF NANOPARTICLES |
AU1396588A (en) * | 1987-02-20 | 1988-09-14 | Emory University | Antiinfective compounds and method of use |
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
EP1659132A1 (en) * | 1987-08-11 | 2006-05-24 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
FR2630115B1 (en) * | 1988-04-14 | 1994-10-28 | Merieux Inst | PROCESS FOR STABILIZING HUMAN ALBUMIN SOLUTIONS AND SOLUTION OBTAINED |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
JPH02107163A (en) * | 1988-10-15 | 1990-04-19 | Suntory Ltd | Production of novel gelatinous food |
US5308834A (en) * | 1989-02-14 | 1994-05-03 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein |
US5171739A (en) * | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
US5089274A (en) * | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
US5234912A (en) * | 1989-02-14 | 1993-08-10 | Incyte Pharmaceuticals, Inc. | Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof |
US5334584A (en) * | 1989-02-14 | 1994-08-02 | Incyte Pharamaceuticals, Inc. | Recombinant, non-glycosylated bpi protein and uses thereof |
US4997664A (en) * | 1989-09-05 | 1991-03-05 | Bryan Foods, Inc. | Method for packaging food products |
EP0563222B1 (en) * | 1990-12-03 | 1998-02-25 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
HUT67762A (en) * | 1991-03-19 | 1995-04-28 | Cytrx Corp | Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof |
US5234908A (en) * | 1991-04-12 | 1993-08-10 | Creative Biomolecules, Inc. | Method of treating gastrointestinal ulcers with platelet derived growth factor |
EP0605653A4 (en) * | 1991-09-26 | 1995-03-15 | Incyte Pharma Inc | A new form of liposaccharide binding protein (lbp). |
WO1993023540A2 (en) * | 1992-05-19 | 1993-11-25 | Xoma Corporation | Improved methods for the preparation of endotoxin-binding proteins |
US5643570A (en) * | 1992-05-19 | 1997-07-01 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
EP0682524B1 (en) * | 1993-02-02 | 2001-10-04 | XOMA Technology Ltd. | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
US5348942A (en) * | 1993-03-12 | 1994-09-20 | Xoma Corporation | Therapeutic uses of bactericidal/permeability increasing protein products |
-
1994
- 1994-02-02 EP EP94907963A patent/EP0682524B1/en not_active Expired - Lifetime
- 1994-02-02 CN CNB941913554A patent/CN1163264C/en not_active Expired - Fee Related
- 1994-02-02 AU AU61330/94A patent/AU695125B2/en not_active Ceased
- 1994-02-02 DE DE69428521T patent/DE69428521T2/en not_active Expired - Fee Related
- 1994-02-02 AT AT94907963T patent/ATE206308T1/en not_active IP Right Cessation
- 1994-02-02 CA CA002155005A patent/CA2155005C/en not_active Expired - Fee Related
- 1994-02-02 ES ES94907963T patent/ES2164098T3/en not_active Expired - Lifetime
- 1994-02-02 WO PCT/US1994/001239 patent/WO1994017819A1/en active IP Right Grant
- 1994-02-02 JP JP51821394A patent/JP3946246B2/en not_active Expired - Fee Related
- 1994-02-02 US US08/190,869 patent/US5488034A/en not_active Expired - Lifetime
- 1994-02-02 PT PT94907963T patent/PT682524E/en unknown
- 1994-02-02 DK DK94907963T patent/DK0682524T3/en active
-
1995
- 1995-06-07 US US08/472,995 patent/US5696090A/en not_active Expired - Fee Related
-
1997
- 1997-12-08 US US08/986,413 patent/US5955427A/en not_active Expired - Fee Related
-
1998
- 1998-12-24 HK HK98115456A patent/HK1014156A1/en not_active IP Right Cessation
-
1999
- 1999-05-17 US US09/313,525 patent/US6066620A/en not_active Expired - Lifetime
-
2000
- 2000-02-11 US US09/502,356 patent/US6255284B1/en not_active Expired - Fee Related
-
2005
- 2005-02-25 JP JP2005052149A patent/JP2005145986A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2155005C (en) | 1999-04-06 |
CN1163264C (en) | 2004-08-25 |
US6255284B1 (en) | 2001-07-03 |
WO1994017819A1 (en) | 1994-08-18 |
PT682524E (en) | 2002-03-28 |
EP0682524B1 (en) | 2001-10-04 |
US6066620A (en) | 2000-05-23 |
US5488034A (en) | 1996-01-30 |
ATE206308T1 (en) | 2001-10-15 |
HK1014156A1 (en) | 1999-09-24 |
AU6133094A (en) | 1994-08-29 |
AU695125B2 (en) | 1998-08-06 |
US5955427A (en) | 1999-09-21 |
DK0682524T3 (en) | 2002-01-28 |
US5696090A (en) | 1997-12-09 |
JPH10513433A (en) | 1998-12-22 |
DE69428521D1 (en) | 2001-11-08 |
JP3946246B2 (en) | 2007-07-18 |
JP2005145986A (en) | 2005-06-09 |
DE69428521T2 (en) | 2002-05-23 |
CN1127992A (en) | 1996-07-31 |
ES2164098T3 (en) | 2002-02-16 |
EP0682524A1 (en) | 1995-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2155005A1 (en) | Pharmaceutical Compositions Containing Bactericidal Permeability Increasing Protein and a Surfactant | |
NL300212I1 (en) | ASP-B28 insulin crystals. | |
CA2138161A1 (en) | Glucagon-like peptide and insulinotropin derivatives | |
CA2113995A1 (en) | Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins | |
MXPA00010241A (en) | Pharmaceutical composition comprising factor viii and neutral liposomes. | |
DE69312947D1 (en) | PROTEIN-BASED MEDICINES WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES | |
CA2413334A1 (en) | Stabilized interleukin 2 | |
MXPA03007942A (en) | Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability. | |
DE69417252T2 (en) | IMPROVED IMMUNOGENIC COMPOSITION AGAINST HUMAN GASTRIN 17 | |
AU2670495A (en) | Ifn-beta liquid formulations | |
WO1998044944A3 (en) | Stabilized human papillomavirus formulations | |
ATE103776T1 (en) | NEW N-(SULFOMETHYL)-N'-ARYLUREAS. | |
EP0161007A3 (en) | Retro - inverso c-terminal hexapeptide analogues of substance p | |
CA2071757A1 (en) | Implant compositions containing a biologically active protein, peptide or polypeptide | |
EP1431391A3 (en) | Rantes mutants and therapeutic applications thereof | |
FI964448A (en) | New biologically active peptide and its preparation | |
CA2247998A1 (en) | Fragments of cr1 and their use | |
AU7533394A (en) | Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel | |
CA2153071A1 (en) | Derivatized calcitonins | |
AU3975693A (en) | Recombinant active forms of ECEF, proteins that associate therewith, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |